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A simple, rapid and robust high-throughput assay for the quantitative analysis of irbe-
sartan in plasma from two species using liquid chromatography tandem mass spectro-
metric method was developed and validated. Solid phase extraction was used and
quantification was achieved using a positive electrospray ionization interface under mul-
tiple reactions monitoring condition. Complete validation (as per recent regulatory re-
quirements) was done using human plasma. The same method was validated using dog
plasma and the validation parameters met respective acceptance criteria. The method has
shorter run time of 3 min. This will help in high throughput. The low aliquot volume in the
method helped us to take enough sampling time points for better pharmacokinetic profiles.
The calibration curve was shown to be linear from 12.1 to 6018.7 ng/ml in human plasma
and 12.1 to 5987.2 ng/ml in dog plasma. This method was successfully applied to samples
collected during bioavailability studies of irbesartan in humans and dogs.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Irbesartan is a synthetic, nonpeptide antagonist of angio-
tensin-II with chemical name 2-butyl-3-({4-[2-(2H-1,2,3,4-, þ91 9818509413 (mobile
.K. Tiwari).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univtetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-
1-en-4-one. Irbesartan is a potent and orally active. It is ex-
pected to block all actions of angiotensin-II mediated by the
AT1 receptor, regardless of the source or route of synthesis of
angiotensin-II. The selective antagonism of the angiotensin-II); fax: þ91 124 4231002.
sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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angiotensin-II levels, and a decrease in plasma aldosterone
concentration [1,2]. Irbesartan does not inhibit ACE (kininase
II), an enzyme, which generates angiotensin-II and also de-
grades bradykinin into inactive metabolites. Structures of
irbesartan and candesartan are provided in Fig. 1.
Over the years, several analytical methods were reported
for determination of irbesartan. These methods included
high-performance liquid chromatography with fluorescence
detection [3e7], high-performance liquid chromatography
with diode array detection [8] and Matrix-assisted laser
desorption time of flight mass spectrometry [9].
Ganeshan et al. [10] reported a method for quantification of
irbesartan in human plasma using liquid chromatography
mass spectrometry. Quantification of irbesartan in these
methods was performed using one of the extraction tech-
niques: solid phase extraction (SPE)/liquideliquid extraction
(LLE)/protein precipitation. Matrix effect related issues have
been observed when LLE has been used. Moreover, LLE is a
tedious process and sample clean-up is also not up to mark.
Achieving better recoveries, cleaner extracts, requirement of
less time for extraction, selective removal of interferences and
matrix components, lower requirement for solvent and
avoiding of formation of emulsions are advantages of solid
phase extraction (SPE) over LLE. One primary advantage is that
SPE renders itself easily to automation. Same is the case when
protein precipitation is used as processing method. Even
though the method is less laborious, the major disadvantage
is that samples are not clean, which leads to high back pres-
sure and matrix effect related issues [11e13].
This article describes a liquid chromatographyetandem
mass spectrometric method for quantifying irbesartan in two
species (human and dog) plasma using candesartan as the
internal standard. For this method, solid phase extraction
technique was used for extraction of plasma sample, which
helps in nullifying the matrix effect. The final reconstituted
sample is clean, which improve column and instrument effi-
ciency. This assay requires a very low aliquot volume of 50 ml
for dog and human plasma. This helps in taking more sam-
pling time points and saving cost. This method has short run
time for measuring irbesartan. So there is a considerable
saving in time that can maximize sample throughput result-
ing in much reduced sample analysis time.
This paper demonstrates a selective, sensitive and high-
throughput LCeMS/MS method for the determination of
irbesartan in dog as well as in human plasma and itsFig. 1 e Structures of irbesartan and candesartan.subsequent application to pharmacokinetic samples.We have
observed that if a method is developed in plasma of one spe-
cies, it is unlikely the same method can be used for plasma of
other species. The precision and accuracy could not be a
concern. However, matrix effect varies from species to spe-
cies. Also the aliquot volume used in dog study has to be as
low as possible. Keeping in mind above, an LCeMS/MS
method using solid phase extraction as processing method
was developed in human plasma and it has been validated for
all parameters as per recent regulatory requirements. The
method has also been validated in dog plasma and all pa-
rametersmet respective acceptance criteria. To the best of our
knowledge, no other LCeMS/MS method for irbesartan in dog
plasma has been published. Compare to several other
methods reported, this method employs a low aliquot volume
of plasma without compromising speed, sensitivity and
selectivity. A complete validation in dog plasma was as per
global regulatory requirements. Matrix effect was nil. This
method has been successfully applied for analysis of plasma
samples obtained from bioavailability studies in humans and
dogs.2. Materials and methods
2.1. Materials
2.1.1. Chemicals and materials
Irbesartan (99.7% pure) was procured from USP and cande-
sartan (internal standard; 98.9% pure) was purchased from
Varda Biotech (Mumbai, India). These were used to prepare
stock solutions. HPLC-grade acetonitrile from Spectrochem
(Mumbai, India) was used for the preparation ofmobile phase.
All aqueous solutions and buffers were prepared using water
that was purified using a Milli-Q Gradient A10 (Millipore,
Moscheim Cedex, France). Cleanert PEP-H 30 mg/ml, solid
phase cartridges were obtained from Agela technologies
(Tianjin, China). Tri potassium ethylene diamine tetra acetic
acid (K3 EDTA) containing plasma batcheswere obtained from
Yash Laboratory (Thane (W), India). Dog plasma was obtained
from drug safety department of Ranbaxy Laboratories Limited
(Gurgaon, India). Respective plasma batches were used to
prepare calibration standards and quality control samples in
human and dog plasma.
2.2. LC/ESIeMS/MS instrumentation and analytical
conditions
The liquid chromatography separationwas performed using a
Shimadzu scientific instruments (Shimadzu Corporation;
Kyoto, Japan) consisted of two LC-20AD delivery pumps, an
on-line DGU-20A3 prominence solvent degasser, an SIL-HTc
Shimadzu autosampler and a CBM-20A prominence column
oven. Liquid chromatographic separations were achieved
using Chromoliths SpeedROD; RP-18e column (50e4.6 mm)
(Merck Scientific, USA). An injection volume of 10 ml was used
for each analysis. Mobile phase consisted of acetonitrile:
ammonium formate solution (70:30, v/v). The flow rate of the
mobile phase was set at 0.500 ml/min. The column and
autosampler were maintained at 35 C  1.0 C and
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API-3000 triple quadrupole mass spectrometer (MDS Sciex;
Toronto, Canada) equipped with an electrospray ionization
source operating in positive ion mode. Nitrogen was used as
the nebulizer, auxillary, collision and curtain gas. Analytes
were detected by tandem mass spectrometry using multiple
reaction monitoring (MRM) of precursor-product ion transi-
tions with 200 ms dwell time, at m/z 427.1 (parent ion)/192.9
(product ion) and 438.9 (parent ion)/308.9 (product ion) for
irbesartan and candesartan (ISTD) respectively. The instru-
ment response was optimized by syringe pump infusion of
irbesartan and candesartan (ISTD) in the mobile phase by
constant flow (10 ml/min) into the stream of the mobile phase
eluting from the LC column. The main working source/gas
parameters of the mass spectrometer were optimized and
maintained as provided in Table 1. Calibration curves were
constructed by calculating the analyte to ISTD peak area ratio
(y) against analyte concentrations (x). Data acquisition and
processing were performed using Analyst version 1.4.1 soft-
ware (MDS Sciex; Toronto, Canada).2.3. Preparation of stock solution, standard and quality
control samples
Stock solutions of irbesartan and candesartan were prepared
in methanol, stored in refrigerator between 1 and 10 C, and
protected from light until use. Subsequent working solutions
of irbesartan for use in calibration curve construction were
prepared by serial dilution of the stock solutions.
A 200 ml aliquot of each working solution was added to
pooled blank K3 EDTA plasma to yield spiked calibration
standards at nine different concentrations ranging from
12.1 ng/ml to 6018.7 ng/ml (in human plasma) and 12.1 ng/ml
to 5987.2 ng/ml (in dog plasma). Simultaneously, quality
control samples for determination of precision and accuracy
in K3 EDTA plasma at four concentrations were prepared in
the similar manner as that of calibration standards. Quality
control samples (QC) were prepared at 12.2, 32.2, 2221.5 and
4443.0 ng/ml using human plasma. Quality control samples
were prepared at 12.2, 33.4, 2385.3 and 4770.5 ng/ml using dog
plasma. Calibration curve plasma standards and quality con-
trol samples were stored at around 20 C until use. The
amount of stock solution in all spiked samples was kept at 2%
of the total sample volume to minimize any systemic errors
between the real samples and spiked samples.Table 1 e Optimized source and compound parameters.
Parameters Irbesartan Candesartan
Declustering potential (V) 50 50
Entrance potential (V) 2.5 3.0
Collision energy (V) 32 30
Clustering cell exit potential (V) 16 26
Temperature (

C) 550 550
Collision associated dissociation 3 3
Curtain gas 30 30
Gas-1 60 60
Gas-2 40 40
Ion spray voltage (V) 4200 42002.4. Sample preparation
Plasma samples stored at around 20 C were thawed on the
day of extraction at room temperature followed by vortexing
to ensure homogenicity. An Eppendorf pipette was used to
aliquot 50 ml of human/dog spiked plasma sample into poly-
propylene tubes (13 mm  50 mm). To each tube then added
50 ml of internal standard (ISTD) stock dilution (approximately
20,000.0 ng/ml of candesartan) with the use of multistepper
and vortexed approximately for 30 s. The samples were vor-
texed to ensure complete mixing of contents. 200 ml of 2% li-
quor ammonia was added in each tube and vortexed. The
cartridges {Cleanert PEP-H 30 mg/ml} were conditioned using
1 ml of HPLC-grade methanol followed by 1 ml of HPLC-grade
water by running centrifuge at 1500 rpm for 1 min. The sam-
ples were loaded on the cartridges and the centrifuge was run
for 2 min at 1500 rpm. The samples were washed with 1 ml of
5% methanol by running centrifuge for 1 min at 1500 rpm
followed by 1 ml of HPLC-grade water. The samples were
eluted twice with 1 ml of methanol by running centrifuge for
1 min at 1500 rpm. The eluted samples were dried under ni-
trogen at 50 C  2 C at about 15 psi. The dried residue was
reconstituted with 0.5 ml of mobile phase. Using an
Eppendorf pipette, the reconstituted samples were trans-
ferred to autosampler vials. 10 ml was injected into the LCeMS/
MS system for analysis. All the samples were processed under
low light conditions.
2.5. Methodology for validation
A full method validation was performed according to guide-
lines set by the USFDA [14]. The validation of this procedure
was performed in order to evaluate the method in terms of
selectivity, sensitivity, linearity of response, accuracy, preci-
sion, recovery, matrix effect, and stability of analyte during
both short-term sample processing and long-term storage.
2.5.1. Selectivity
The selectivity of the method towards endogenous
plasma matrix components was assessed in six lots of blank
human/dog plasma. They were processed and analyzed using
the proposed extraction protocol and the set chromatographic
conditions for irbesartan at the lower limit of quantitation
(LLOQ) level.
2.5.2. Linearity and LLOQ
The linearity of the method was determined by analysis of
standard plots associated with a nine-point standard cali-
bration curve in each plasma species. Calibration curves from
accepted three precision and accuracy batches were used to
establish linearity. Peak area ratios of analyte/ISTD obtained
from MRM were utilized for the construction of calibration
curves; using weighted (1/x2) linear least squares regression of
the plasma concentrations and themeasured peak area ratios.
Back calculations were made from these curves to determine
the concentration of irbesartan in each calibration standards
and the resulting calculated parameters were used to deter-
mine concentrations of analyte in quality control or unknown
samples. The correlation coefficient r > 0.98 was desirable for
all the calibration curves. The lowest standard on the
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lyte response was at least five times more than that of drug
free (blank) extracted plasma. In addition, the analyte peak of
LLOQ sample should be identifiable, discrete, and reproducible
with accuracy within 20.0% and a precision 20.0%. The
deviation of standards other than LLOQ from the nominal
concentration should not be more than 15.0%.2.5.3. Accuracy and precision
Intra- and inter-day accuracies were expressed as a percent-
age of deviation from the respective nominal value and the
precision of the assaywasmeasured by the percent coefficient
of variation (% CV) at concentrations. Intra-day precision and
accuracy were assessed by analyzing six replicates of the
quality control samples at four levels during a single analyt-
ical run. The inter-day precision and accuracy were assessed
by analyzing eighteen replicates of the quality control sam-
ples at each level through three precision and accuracy
batches runs on two consecutive validation days in both dog
and human plasma samples. The deviation at each concen-
tration level from the nominal concentration was expected to
be within 15.0% except lower limit of quality control
(LLOQC), for which it should not be more than 20.0%. Simi-
larly, the mean accuracy should not deviate by 15.0% except
for the LLOQC, where it can be 20.0% of the nominal
concentration.2.5.4. Recovery
The relative extraction recoveries for the analyte and ISTD at
low, middle and high QC concentration levels were deter-
mined by measuring the mean peak area response of six
replicates of extracted quality control samples against the
mean peak area response of six replicates each of three neat
solutions containing analyte and a neat solution containing
ISTD at concentrations equivalent to those obtained in the
final extracted concentration for the analyte and ISTD in the
quality control samples. It was assessed using human as well
as dog plasma.
2.5.5. Matrix effect and matrix factor
Matrix effect was assayed at two concentration levels (LLOQC
and HQC). Six different blank human/dog plasma lots (four
normal, one haemolysed, one lipemic), free of any significant
interference at the RT of analyte and ISTD, were selected and
spiked with the working solutions of LLOQC and HQC (high
quality control). Spiked samples from each plasma lot were
processed in duplicate and quantitated against freshly spiked
calibration curve. The matrix effect is validated to be nullified
if the accuracy and precision do not deviate by15.0% for HQC
and 20.0% for LLOQC of the nominal concentration. The
matrix factor is defined as the peak area response in the
presence of matrix ions versus the peak area response in the
absence of matrix ions. Since this method involved terminal
drying step, biological matrix samples were prepared by
reconstituting the post-extracted blank plasma samples with
three neat solutions containing irbesartan and candesartan at
concentration representing the final extracted concentration
for the analyte (low, medium and high quality control con-
centration) and ISTD. The control sampleswere the same neatsolutions prepared in the mobile phase. Matrix factor was
evaluated using six different blank plasma lots (four normal,
one haemolysed, one lipemic) and determined by measuring
the respective mean peak area response and mean analyte/
ISTD peak area ratio (ISTD normalizedMF) of biological matrix
sample against the mean peak area response and mean ana-
lyte/ISTD peak area ratio of neat solutions.
2.5.6. Stability
The absolute stability of irbesartan in human/dog plasmawas
assessed by analyzing four replicates of QC samples at low
and high concentrations during the sample storage and pro-
cessing procedures. Bench-top stability was assessed in
human/dog plasma for 7.25 h/7.50 h, which exceeds the resi-
dence time of the sample processing procedures. The freeze-
thaw stability was evaluated after undergoing three freezes
(at around 20 C)-thaw cycles. Long-term stability was
assessed after storage of the test samples at around20 C for
sixty-eight days in human plasma and seventy two days in
dog plasma. The autosampler storage stability was deter-
mined by storing the reconstituted QC samples for 54.97 h/
55.25 h under autosampler condition (maintained at 10 C)
before being analyzed. All stability exercises were performed
against freshly spiked calibration standards processed along
with freshly spiked four replicates of QC samples at low and
high concentrations, which act as comparison samples for
determining the percentage absolute stability of irbesartan
during the sample storage and processing procedures. The
analyte was considered stable in plasma at each concentra-
tion if the mean calculated concentration of stability samples
does not deviate by 15.0% of the mean calculated concen-
tration of comparison quality control samples. The working
solutions and stock solutions of irbesartan and ISTDwere also
evaluated for their stability at room temperature for 8 h and at
refrigerator temperature (between 1 and 10 C) for 16 d,
respectively. All stability exercises were performed both in
human as well as dog plasma.
2.6. Method application
In humans, an open label, balanced, randomized, two-
treatment, two-period, two-sequence, single-dose, crossover
design was used for the assessment of pharmacokinetics and
bioavailability. Twenty-four healthy adult male volunteers
who gave written informed consent took part in this study.
The study was approved by Ethics Committee of Institutional
Review Board at Fortis Hospital (India). After an overnight fast
of at least 10 h, all subjects were given a single oral dose of
Irbesartan 300 mg tablet (Test formulation) of Ranbaxy and
AVAPRO tablets 300 mg (Reference formulation) of Bristol-
Myers Squibb during each period of the study. Blood sam-
ples were collected before and at 0.250, 0.500, 0.750, 1.000,
1.250, 1.500, 1.750, 2.000, 2.250, 2.500, 2.750, 3.000, 3.333, 3.667,
4.000, 4.500, 5.000, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000
and 48.000 h post-dose in each period. A washout period of
seven days was kept between two periods of the study. The
plasma was immediately separated by centrifugation and
stored frozen at around 20 C until analysis. Irbesartan
concentrations were obtained after analysis of plasma
samples.
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treatment, two-period, two-sequence, single-dose, crossover
design was used for the assessment of pharmacokinetics and
bioavailability. Twelve healthy adult male dogs were used in
the study. The study was approved by Institutional Animal
Ethics Committee (India). After an overnight fast of at least
10 h, all dogswere given a single oral dose of Irbesartan 300mg
tablet of Ranbaxy and AVAPRO tablets 300 mg of Bristol-
Myers Squibb during each period of the study. Blood sam-
ples were collected before and at 0.5, 1.0, 2.0, 2.5, 3.0, 3.5, 4.0,
4.5, 5.0, 6.0, 8.0, 12.0, 24.0, 36.0, 48.0 h post-dose in each period.
A washout period of six days was kept between two periods of
the study. The plasma was immediately separated by centri-
fugation and stored frozen at around 20 C until analysis.
Irbesartan concentrations were obtained after analysis of
plasma samples.
The pharmacokinetic parameters were calculated for
irbesartan using WinNonlin pharmacokinetic Software
version 5.0.1 in human and dog studies. These were area
under the plasma concentration versus time curve, from time
zero to the last measurable concentration (AUC0/t); the area
under the plasma concentration versus time curve, from time
zero to infinity (AUC0/N); maximum measured plasma con-
centration (Cmax); time of the maximum measured plasma
concentration (Tmax), and the apparent first-order terminal
elimination half-life (t1/2). Statistical analysis was performed
using statistical analysis system software (SAS) version 9.1.
Analysis of variance (ANOVA) was performed on the log nat-
ural (ln)-transformed pharmacokinetic parameters Cmax,
AUC0et and AUC0eN using Type III sum of squares, with the
main effects of formulation, period, sequence and animal/
subject nested within sequence. A separate ANOVA model
was used to analyze each of the parameters. The sequence
effect was tested at the 10% level of significance using the
animal/subject nested within sequence mean square as the
error term. Formulation and period effects were tested at the
5% level of significance against the residual error (mean
square error) from the ANOVA model as the error term. Each
ANOVA included calculation of least-squares means (LSMs),
the difference between the adjusted formulation means and
the standard error associated with the difference.
Ratio of the test (T) and reference (R) formulation averages
(least square means) were calculated for irbesartan by first
calculating the differences in the averages (arithmetic means)
of the log-transformed data and then taking the antilog of the
obtained differences for human and dog studies. The com-
parison of interest was test vs reference (T vs R), so the ratios
were of the form: Test/Reference (T/R). Ratio of means was
calculated using the LSM for log-transformed pharmacoki-
netic parameters (AUC0et, AUC0eN and Cmax). Ratio of means
was expressed as a percentage of the LSM of the reference
formulation.3. Results and discussion
3.1. Optimization of the mass spectrometric condition
Irbesartan certainly the mass spectrometric detection in
positive ion mode was evaluated using both electrosprayionization (ESI) as well as atmospheric pressure chemical
ionization (APCI). The signal intensity obtained in the positive
mode with ESI interface is much higher than that of APCI. The
Q1 ESI spectra were dominated by the protonated quasimo-
lecular ion [M þ H]þ at m/z 427.1 for irbesartan and 438.9 for
candesartan. The MS/MS parameters, including the declus-
tering potential (DP), focusing potential (FP), collision cell exit
potential (CXP), gases (NEB, CAD) and collision energy (CE),
were optimized to identify the most stable and intense prod-
uct ion for the analyte and ISTD. The parent ions at m/z 427.1
for irbesartan and 438.9 for candesartan, were observed with
higher abundance and greater stability. During the method
development different additives of varying strength were
added to the mobile phase, so as to obtain higher abundance
of protonated parent ion of analyte and ISTD. Use of ammo-
nium formate solution of strength 5  0.1 mM in the mobile
phase enhances the occurrence of [M þ H]þ and eventually
results in an improvement in area response for both the an-
alyte and ISTD.
3.2. Optimization of chromatographic condition
A number of reversed-phase columns, such as Ascentis-C18,
Hypersil-C18, Zorbax SB-CN, Chromoliths SpeedROD and
Phenomenex Luna, were tested to obtain optimal selectivity,
efficiency, suitable retention time and symmetric peak shape
for the analyte and ISTD. In industrial research cutting of the
separation time is always in focus in order to attain the high
throughput. The Chromoliths SpeedROD column (50e4.6 mm)
was selected since it provided good peak shape and better
sensitivity with greater signal to noise (S/N) ratio. The chro-
molith columns are composed of porous silica rods with
w2 mmmicropores, which facilitates fast mass transfers and
results in minimizing the total analytical run time to 3.0 min.
The mobile phase consisting of 5  0.1 mM ammonium
formate and acetonitrile gave higher signal intensity. Aceto-
nitrile was chosen as organic phase over methanol as it
revealed a higher mass spectrometric response and with
minimal background noise. Change in percentage of acetoni-
trile in the mobile phase was found to have profound influ-
ence on retention time and peak shape. Thus a mobile phase
consisting of acetonitrile: 5  0.1 mM ammonium formate
solution (70:30, v/v) was used in the experiment. Under these
conditions, irbesartan and candesartan elute at retention time
of approximately 1.2 min.
3.3. Sample preparation optimization
Sample clean-up was focused on solid phase extraction since
this techniquemostly provides the cleanest sample compared
to protein precipitation or liquideliquid extraction. During
initial stages of the method development, three reversed-
phase type solid phase polymeric supports (Waters Oasis
HLB; Agilents Bond Elut Plexa; and Agelas Cleanert PEP-H)
were tested for the extraction of analyte and ISTD from
human/dog plasma. All the three polymeric supports nearly
produced comparable results. In this work, we have utilized
Cleanert PEP-H cartridges for isolation of analyte and ISTD
from the plasma samples with minor modification. Further-
more, the use of internal standard compensated for any
Fig. 2 e Representative chromatograms of irbesartan and candesartan (ISTD) in human plasma: blank (A), blankD ISTD (B),
LLOQ (C) and ULOQ (D) samples.
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method. The extraction procedure described here offers a
rapid way to isolate analyte as well as ISTD from plasma
matrix.
3.4. Method validation
3.4.1. Selectivity
Selectivity is the ability of an analytical method to differen-
tiate and quantify the analyte in the presence of other com-
ponents in the sample. Selectivity was ascertained in different
batches of human/dog plasma by comparing the chromato-
grams of blank plasma samples with the corresponding
spiked LLOQ plasma samples. Fig. 2 shows the typical chro-
matograms of a double blank, blank spiked with ISTD, aTable 2 e Summary of calibration curve from precision
and accuracy batches in human plasma (n[ 3).
Nominal
concentration
(ng/ml)
Mean observed
concentration
(ng/ml)
Precision
(%)
Accuracy
(%)
12.1 12.57  0.06 0.5 103.9
31.4 29.43  0.23 0.8 93.7
74.8 68.90  2.54 3.7 92.1
187.0 179.57  4.06 2.3 96.0
424.9 434.50  4.87 1.1 102.3
1180.3 1241.10  11.85 1.0 105.2
2226.9 2251.20  7.30 0.3 101.1
4453.9 4695.67  47.63 1.0 105.4spiked plasma samplewith irbesartan at LLOQ and upper limit
of quantitation (ULOQ) level. As it can be seen no interference
peak from endogenous compounds was observed at the
retention time of the analyte and ISTD.
3.4.2. Linearity and sensitivity
The method was validated using the above criteria and found
that plasma calibration standard curve containing irbesartan
was linear over the concentration range of 12.1e6018.7 ng/ml
in human plasma (Table 2) and 12.1e5987.2 ng/ml in dog
plasma (Table 3). The intercept with the y-axis was not
significantly different from zero. A typical regression equation
was y ¼ 0.0359x þ 0.0331 with a correlation coefficient (r) of
0.9987, where y represents the peak area ratio of irbesartan to
that of ISTD and x represents the plasma concentration ofTable 3 e Summary of calibration curve from precision
and accuracy batches in dog plasma (n[ 3).
Nominal
concentration
(ng/ml)
Mean observed
concentration
(ng/ml)
Precision
(%)
Accuracy
(%)
12.1 12.40  0.10 0.8 102.5
32.2 30.20  0.95 3.2 93.8
76.6 71.20  1.65 2.3 93.0
191.6 181.00  2.62 1.4 94.5
479.0 436.70  8.23 1.9 91.2
1197.4 1222.10  18.25 1.5 102.1
2394.9 2255.60  13.29 0.6 94.2
4789.8 4720.97  61.58 1.3 98.6
5987.2 6055.23  130.43 2.2 101.1
Table 4 e Accuracy and precision of the method for the estimation of irbesartan in human and dog plasma.
Matrix Nominal
concentration
(ng/ml)
Intra-day (n ¼ 6) Inter-day (n ¼ 18)
Mean  SD (ng/ml) Accuracy (%) CV (%) Mean  SD (ng/ml) Accuracy (%) CV (%)
Human
plasma
12.2 13.43  0.46 110.1 3.4 13.46  0.71 110.3 5.3
32.2 30.28  0.88 94.0 2.9 30.86  0.99 95.8 3.2
2221.5 2223.32  7.81 100.1 0.4 2224.53  10.77 100.1 0.5
4443.0 4438.52  8.87 99.9 0.2 4440.93  12.25 100.0 0.3
Dog
plasma
12.2 13.17  0.64 107.9 4.8 13.20  0.56 108.2 4.2
33.4 31.43  0.34 97.6 1.1 30.99  0.82 92.8 2.6
2385.3 2379.60  2.69 107.1 0.1 2374.34  9.43 99.5 0.4
4770.5 4768.52  3.35 107.3 0.1 4770.02  11.23 100.0 0.2
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12.1 ng/ml, to match study sensitivity requirements, at which
the obtained values were within 8.0% of the spiked values
and the intra- and inter-day coefficients of variation were
<5.5% in both species (Table 4). LLOQ of 12.1 ng/mlwas chosen
in order to estimate irbesartan in plasma samples until 48 h in
both the species plasma samples.
3.4.3. Precision and accuracy
Precision and accuracy of the method were determined by
analyzing quality control samples at four concentrations
within the calibration curve range to validate reproducibility.
Table 4 summarizes the inter- and intra-day precision and
accuracy values for quality control samples. The coefficient of
variation (CV) values of both intra- and inter-day results ob-
tained in both species plasma was below 4.8% and 5.3%,
respectively. Intra- and inter-day accuracies were less than
10.5% at all analyte concentrations in both the species.
These results above indicate that the present method has
good accuracy, precision and reproducibility in human as well
as dog plasma.
3.4.4. Recovery
At three QC concentration levels 32.2, 2221.5 and 4443.0 ng/ml
the relative extraction recovery (mean  SD) for irbesartan in
human plasma was 73.2  4.5%, 78.0  9.5% and 80.2  1.0%,Table 5 e Stability data for irbesartan in human and dog
plasma under various conditions.
Stability Result in human
plasma
Result in
dog plasma
Freeze-thaw stability
(%) at LQC, HQC
100.8, 100.4 99.8, 101.3
Freeze-thaw stability
(cycles)
Three Three
Bench-top stability (%)
at LQC, HQC
96.3, 102.5 97.8, 98.5
Bench-top stability
duration (h)
7.25 7.50
Auto sampler stability
(%) at LQC, HQC
97.4, 98.6 95.2, 97.5
Auto sampler stability
duration (h)
54.97 55.25
Long-term stability (%)
at LQC, HQC
109.1, 98.2 106.4, 96.2
Long-term stability
duration (d)
68 72respectively. The mean recovery for the internal standard
candesartan at the concentration employed was 65.1  7.7%.
At three QC concentration levels 33.4, 2385.3 and 4770.5 ng/
ml the relative extraction recovery (mean  SD) for irbesartan
in dog plasma was 75.6  6.5%, 81.2  7.8% and 85.3  3.0%,
respectively. The mean recovery for the internal standard
candesartan at the concentration employed was 68.6  6.5%.
The result indicates that the extraction efficiency for irbe-
sartan using solid phase extraction was satisfactory, consis-
tent and was not concentration dependent.
3.4.5. Matrix effect and matrix factor
Matrix effect, ion suppression or enhancement, due to the co-
eluting endogenous component of sample matrix along with
the analyte or internal standard may affect the chromatog-
raphy and accuracy of analytical method when developing
LCeMS/MS assay. So, to ensure the selectivity of method,
matrix effect aswell asmatrix factor on the presentedmethod
was evaluated following the procedures described above. Re-
sults obtained therein indicate that no additional variations in
plasma concentration due to the use of different plasma lots
were observed. Hence the concentration of the analyte ob-
tained from study samples should therefore be considered as
reliable. The matrix ionization suppression or enhancement
of the analyte and ISTDwas assessed bymeasuring thematrix
factor at three QC concentration levels. The mean absolute
matrix factor at the low, medium and high QC concentrations
from six lots of human plasma samples was 0.82, 0.86, and
0.85, respectively. The CVs of absolute matrix factor and ISTD
normalized matrix factor from six lots of human plasma
samples were <2.4%. The mean absolute matrix factor at the
low, medium and high QC concentrations from six lots of dog
plasma samples was 0.72, 0.83, and 0.86, respectively. The CVs
of absolute matrix factor and ISTD normalized matrix factor
from six lots of dog plasma sampleswere<3.4%. These results
showed that ion suppression or enhancement from the
plasma matrix was negligible under the current conditions.
3.4.6. Stability studies
The absolute stability of irbesartan was investigated at two
concentration levels of QC samples (low and high) in human
and dog plasma to cover expected conditions during analysis,
storage and processing of all samples, which include the sta-
bility data from various stability exercise like in-injector,
bench-top, freeze-thaw and long-term stability tests. The
stability results summarized in Table 5 showed that irbe-
sartan spiked into human/dog plasma was stable for at least
Fig. 3 e The linear mean plasma concentration versus time profile of irbesartan in human plasma: reference formulation
(,); test formulation (6).
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10 C under autosampler storage condition, for 68 d/72 d at
around 20 C and during three freeze-thaw cycles. The stock
solutions of irbesartan and ISTD were found stable at refrig-
erator temperature (between 1 and 10 C) for 12 d and the
working solutions of irbesartan and ISTD were found stable
for about 8 h at room temperature.
3.5. Method application
This developed method was applied to a pharmacokinetic
study of irbesartan in twenty-four healthy adult male human
volunteers following oral administration of 300 mg of irbe-
sartan tablet. The mean concentrationetime profile of irbe-
sartan in these volunteers is shown in Fig. 3.
Noncompartmental analysis for deriving pharmacokinetic
parameters was performed withWinNonlin version 5.0.1. The
actual time of sample collection was used for pharmacoki-
netic analysis of irbesartan. The mean estimated pharmaco-
kinetic parameters derived from the plasma concentration
profiles are summarized in Table 6. Based on the ANOVATable 6 e Pharmacokinetic parameters (mean ± SD) of irbesart
reference formulations to humans/dogs.
Parameters Human data
Reference Test
Tmax (h) 2.1  1.1 2.2 
Cmax (ng/ml) 3801.7  801.6 4013.0 
AUC0et (ng.h/ml) 21,260.4  5230.8 22,320.4 
AUC0eN (ng.h/ml) 21,615.7  5295.0 22,741.2 
T1/2 (h) 8.7  1.8 9.1 results from human study, no significant formulation, period
and sequence effect was observed for log-transformed PK
parameters Cmax, AUC0et and AUC0eN. The ratios of test (T)
and reference (R) formulations least square means derived
from the analysis of log-transformed pharmacokinetic pa-
rameters AUC0eN, AUC0et, and Cmax. Point estimates of test/
reference mean ratio for Cmax, AUC0et, and AUC0eN were
103.26%, 104.17% and 104.44% in human study.
This developed method was also applied to a pharmaco-
kinetic study of irbesartan in twelve healthy adult beagle
dogs following oral administration of 300 mg of irbesartan
tablet. The mean concentrationetime profile of irbesartan in
these dogs is shown in Fig. 4. Noncompartmental analysis for
deriving pharmacokinetic parameters was performed with
WinNonlin version 5.0.1. The actual time of sample collec-
tion was used for pharmacokinetic analysis of irbesartan.
The mean estimated pharmacokinetic parameters derived
from the plasma concentration profiles are summarized in
Table 6. Based on the ANOVA results from dog study, no
significant formulation, period and sequence effect was
observed for log-transformed PK parameters Cmax, AUC0et,an, after administration of an oral dose of 300 mg test or
Dog data
Reference Test
1.3 1.3  0.8 1.1  0.6
1278.6 7724.18  3337.1 10,056.0  5799.2
6513.0 15,454.9  8418.8 18,017.2  9582.7
6530.1 16,390.9  9053.7 18,647.7  10,238.1
2.1 7.5  5.5 5.9  3.9
Fig. 4 e The linear mean plasma concentration versus time profile of irbesartan in dog plasma: reference formulation (,);
test formulation (6).
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lations least square means derived from the analysis of log-
transformed pharmacokinetic parameters AUC0eN, AUC0et,
and Cmax. Point estimates of test/reference mean ratio for
Cmax, AUC0et, and AUC0eN were 125.92%, 119.01% and
115.25% in dog study.4. Conclusion
A rapid, sensitive and selective LCeMS/MS method for the
quantitation of irbesartan was developed and validated par-
allelly in human and dog plasma. The assay was linear from
12.1 to 6018.7 ng/ml in human plasma and 12.1e5987.2 ng/ml
in dog plasma. The lowest standard generated typical signal to
noise ratios around 200. Solid phase extraction methodology
was adopted in plasma sample preparation, which provides
consistent extraction recovery with minimal endogenous
interference and matrix effect. Irbesartan was found stable
during storage, processing, and analysis in human/dog
plasma samples. The results indicate the method to be sen-
sitive, selective, accurate and reproducible. The applicability
of the method was demonstrated in bioavailability studies of
irbesartan in healthy male human volunteers as well as
healthy male dogs. Moreover, high throughput and low
aliquot volume will help in cost savings.
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